Harrow Strengthens Retina Portfolio with Positive Clinical Data at ASRS 2026
Event summary
- Harrow presented three studies supporting IHEEZO® and BYOOVIZ® at the ASRS 2026 Annual Meeting on July 20, 2026.
- Interim findings from a randomized study of 150 patients showed encouraging trends toward less post-procedure pain with IHEEZO versus subconjunctival lidocaine.
- A real-world study evaluated nearly 20,000 injections and found no increased endophthalmitis risk with IHEEZO's low-viscosity gel formulation.
- Samsung Bioepis presented interim findings from a large-scale, real-world post-marketing surveillance study of BYOOVIZ.
The big picture
Harrow's presentation of clinical data at ASRS 2026 underscores its strategy to build a robust retina franchise through evidence-driven product adoption. The company is positioning itself as a long-term partner for retina specialists, leveraging both innovative formulations like IHEEZO and biosimilars like BYOOVIZ to capture market share in the ophthalmology sector.
What we're watching
- Clinical Validation
- How the topline data from the QUELL trial in Q4 2026 will impact IHEEZO's market adoption.
- Market Positioning
- Whether Harrow can sustain momentum with BYOOVIZ against established competitors like LUCENTIS.
- Regulatory Dynamics
- The pace at which real-world evidence for IHEEZO and BYOOVIZ influences prescribing patterns among retina specialists.